script.reportAU
Register
← The record

Influenza Vaccine

Noted VaccinesNot applicableNot applicable line

Prevention of influenza caused by Influenza Virus, Types A and B in all persons aged 50 years and older in Australia.

2
Submissions
2007–07
On the record
$15k–45k
ICER range
2 sourced ICERs · 2007
ICER stated
Cost basis

Decisions on record

10 decisions
  • Meeting Mar 2026 Noted Prevention of influenza no PSD
  • Meeting Jul 2025 Withdrawn Prevention of influenza no PSD
  • Meeting Jul 2025 Recommended Prevention of influenza no PSD
  • Meeting Mar 2024 Recommended Prevention of influenza in children aged 6 months to <5 years
  • Meeting Mar 2024 Recommended Prevention of influenza in people aged 65 years and over
  • Meeting Nov 2009 Recommended Vaccine for Influenza no PSD
  • Meeting Jul 2009 Recommended Influenza virus
  • Meeting Apr 2008 Recommended Influenza vaccination no PSD
2 earlier decisions
  • Nov 2007 Not recommended Influenza
  • Mar 2007 Recommended Vaccine no PSD

Access path

2 submissions · public record
  1. Nov 2007
    Not recommended

    Uncertainty in clinical benefits in terms of hospitalisation and mortality, insufficiently substantiated assumption…

  2. Nov 2007
    Not recommended

    uncertainty in clinical benefits in terms of hospitalisation and mortality, uncertainty about modelled economic…

RecommendedDeferredNot recommended

Cost-effectiveness

2 sourced ICERs · 2007

Base case modelled incremental discounted cost/extra discounted QALY of less than $15,000, increasing to $15,000-$45,000 if Jefferson (2007) Cochrane review values were used.

The PBAC considered that there was high sensitivity of the cost per QALY saved due to the assumptions used in the model. PBAC · 2007

Decision context

PopulationAll Australians aged 50 years and older, seeking extension of NIP listing beyond current coverage (aged 65+ and at-risk Aboriginal and Torres Strait Islander persons).

Why it was knocked back

  • uncertainty in clinical benefits in terms of hospitalisation and mortality, uncertainty about modelled economic evaluation results, insufficiently substantiated reduction in hospitalisation and mortality rates, lack of inclusion of a decrement of response to vaccine with age, high sensitivity of cost per QALY saved to model assumptions

Submission history

2 entries
DecidedOutcomeComparatorICEREvidence
Nov 2007 Not recommended current influenza vaccination practice in persons aged 50–64 years (including influenza vaccination through the PBS, pri $15k–45k RCT, Meta-analysis · ILI, serologically confirmed influenza, hospitalisations
Nov 2007 Not recommended current influenza vaccination practice in persons aged 50–64 years (PBS, private prescribing, and leakage through NIP) $15k–45k RCT

Similar precedents

By decision profile
Influenza Vaccine, Injection78%Inactivated Trivalent Influenza Vaccine (Split Virion)73%Oseltamivir72%Influenza Vaccine, Adjuvanted Quadrivalent And Adjuvanted Trivalent72%Influenza Vaccine, Adjuvanted71%Quadrivalent Influenza Vaccine71%Inactivated Quadrivalent Influenza Vaccine70%Quadrivalent Recombinant Influenza Vaccine70%